It is widely accepted that functional ABCA1 is critical for the formation of nascent high-density lipoprotein (HDL) particles. However, the cholesterol pool(s) and the cellular signaling processes utilized by the ABCA1-mediated pathway remain unclear. Sphingomyelin maintains a preferential interaction with cholesterol in membranes and its catabolites, especially ceramide, are potent signaling molecules that could play a role in ABCA1 regulation or function. To study the potential role of ceramide in this process, we treated a variety of cell lines with 20 µM C2 ceramide and examined apolipoprotein-mediated cholesterol efflux to lipid-free apoA-I. We found that cell lines expressing ABCA1 displayed two to three fold increases in cholesterol efflux to apoA-I. Cell lines not expressing ABCAI were unaffected by ceramide. We further characterized the cholesterol efflux effect in Chinese hamster ovary (CHO) cells.
INTRODUCTION
The importance of circulating plasma high density lipoprotein (HDL) is implicit from several population studies showing a inverse correlation between plasma HDL concentration and cardiovascular disease risk (1;2). A major function of HDL is to transport excess cholesterol from extrahepatic tissues back to liver for excretion into the bile (3). This process is often referred to as "reverse cholesterol transport" (4) . It is clear that functional ABCA1 is critical for the formation of HDL in vivo as patients with Tangier disease or familial HDL deficiency have vastly reduced plasma HDL values (5) (6) (7) (8) (9) (10) . Consequently, ABCA1 has been studied extensively as a target for promoting excess cholesterol release from cells.
The first step in HDL formation involves a specific interaction of lipid-poor apoA-I, the major protein component of HDL, with cell surface ABCA1. There is evidence that apoA-I binds to ABCA1 directly (11) (12) (13) , however, it has also been suggested that apoA-I may bind to a lipid domain created by ABCA1 activity (14) .
Regardless of the interaction, the end result is a nascent HDL particle containing apoA-I, phospholipids, and cholesterol. It remains unclear if apoA-I obtains phospholipids and cholesterol together (15;16) , or in a two-step process involving apoA-I receiving phospholipids before obtaining cholesterol (10;17) .
Two possibilities exist for the source of cholesterol utilized by ABCA1 -plasma membrane or intracellular. Evidence exists that ABCA1 may utilize plasma membrane cholesterol from isolated lipid rafts (18) or caveolae (19;20) , although one study showed that ABCA1 does not utilize detergent (Triton) isolated raft cholesterol (21) . It was known well before the discovery of ABCA1 that apoA-I can obtain cholesterol from intracellular sources (22) (23) (24) . More recently, a study looking specifically at ABCA1-mediated cholesterol efflux showed that an endosomal/lysosomal pool is a preferred source (25) .
A complete mechanism for the regulation and transport of cholesterol to ABCA1 accessible pools has not been established. Several signaling molecules have been implicated in apolipoprotein or ABCA1-mediated cholesterol efflux including phospholipases C (PLC) and D (PLD) (26;27) , protein kinase C (PKC) (28) (29) (30) , LXR/RXR ligands (31) (32) (33) (34) (35) , and cyclic AMP (cAMP) (36;37) . In the case of PLC, PLD, and PKC, it is thought that these molecules control cholesterol transport to ABCA1.
Another potential tactic the cell can employ to regulate cholesterol availability to ABCA1 is with membrane sphingomyelin content. Evidence suggests that cholesterol maintains a preferential contact with sphingomyelin in cellular membranes (38) (39) (40) . By modulating sphingomyelin content with sphingomyelinases, cholesterol could either be made available to or sequestered from ABCA1. The majority of sphingomyelin exists in the plasma membrane, however, roughly 25% of cellular sphingomyelin is contained in the lysosomes, endosomes, and golgi combined (41) . These cellular locations of sphingomyelin coincide with hypothesized sources of ABCA1 accessible cholesterol pools (18-20;25) . The digestion of sphingomyelin with sphingomyelinases yields ceramide, a potent lipid signaling molecule shown to potentiate a variety of cellular events including cell growth, apoptosis, cell differentiation, and the stress response (42) (43) (44) (45) . Therefore, as cholesterol is released from an interaction with sphingomyelin by sphingomyelinase activity, the released ceramide could be envisioned to activate a pathway that transports or makes available cholesterol to an ABCA1-accessible pool.
The current study was designed to test the hypothesis that ceramide may play a role in ABCA1-mediated cholesterol efflux. To test this, we treated several cell-types with C2-ceramide. It was found that ceramide treatment increased cholesterol efflux to apoA-I only in cells expressing ABCA1. This effect was further characterized in Chinese hamster ovary (CHO) cells. The major findings were that ceramide treatment increases total and cell surface levels of ABCA1 protein, leading to increased apolipoprotein binding and cellular cholesterol efflux. 
EXPERIMENTAL PROCEDURES

Materials -
Louis, MO).
Egg phosphatidylcholine was acquired from Avanti Polar lipids (Birmingham, AL). SDS-PAGE gels (Redi-gels) were from Bio-Rad (Hercules, CA).
All other chemical reagents were of the highest grade from Fisher (Pittsburgh, PA).
Cell Culture -SMCs were grown in smooth muscle basal medium (SmBM) with SmGM-2 BulletKit supplements and maintained as per manufacturer instructions. HeLa cells and RAW macrophages were grown in DMEM with 10% FBS, 10 µg/ml gentamycin (DMEMg). CHO cells were maintained in Ham's F-12 with 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin (HAMSg). GFP-ABCA1 expressing CHO cells were grown in HAMSg supplemented with 2 mg/ml of G418. GFP-ABCAI expressing HeLa cells were maintained as described previously (46) . All cells were maintained at 37 o C in a humidified 5% CO 2 atmosphere (cell culture incubator).
Sphingolipids were added from stock ethanolic solutions with the final media concentration of ethanol always less then 0.5%. Hypodiploid Nuclei Determination -Performed as described previously (47) . Briefly, cells were grown in T-75 culture flasks and subjected to the experimental culture Student's t-test was used to determine statistical differences.
Cholesterol Efflux Experiments
RESULTS
C2-ceramide treatment increases cholesterol efflux to apoA-I in cells expressing ABCA1
-As stated above, the intimate relationship between sphingomyelin and cholesterol led us to hypothesize that sphingomyelin breakdown products might play a role in the cellular regulation of cholesterol efflux. For our initial studies of ABCA1-dependent cholesterol efflux in vitro, we chose CHO cells and primary human aortic smooth muscle cells (aSMCs). Both cell lines contain relatively high levels of ABCA1 (52) and span the spectrum between easy to manipulate transformed cell models (CHO) and primary human cells that are relevant to the atherosclerotic disease process in the arterial wall (aSMC) (17) . The presence of ABCA1 in these cells was confirmed by western blot analysis (data not shown). For this study, we intentionally avoided the use of pharmacological induction of ABCA1 expression (such as cAMP induction of ABCA1 in RAW macrophages) that would undoubtedly confound any conclusions drawn about ABCA1 regulation. To examine the potential effect of ceramide on cholesterol efflux, we treated both cell types with C2 ceramide, a cell permeant ceramide analog. Figure 1 shows a clear dose-dependent increase in cholesterol efflux to lipid-free apolipoprotein A-I with ceramide treatment in both cell types. We also tested two other sphingomyelin metabolites, sphingosine and sphingosine phosphate, but no consistent effect on cholesterol efflux to apoA-I was observed with either compound (not shown).
Since ceramide showed a clear and consistent effect in both cell types, we treated RAW 264 macrophages (without cAMP stimulation) and HeLa cells with 20 µM C2-ceramide. Both of these cell lines have been shown to lack detectable levels of ABCA1 (12;53). These previous findings were confirmed by western blotting (data not shown). We also investigated whether treatment with C2-dihydroceramide, an analog of C2-ceramide that does not cause apoptosis (57), could stimulate cholesterol efflux. C2-dihydroceramide differs from C2-ceramide by the absence of a 4-5 trans double bond.
Cells are known to take up both compounds to similar extents over 24 h (57) . Figure 3 shows that C2-dihydroceramide treatment causes ceramide-induced cholesterol efflux to levels equivalent to C2-ceramide. Taken with the data in Table 1 , this result suggests that ceramide-induced cholesterol efflux is not caused by an apoptotic mechanism or general cell cytotoxicity.
Ceramide-induced efflux in CHO cells demonstrates specificity to apolipoprotein
acceptors, is fully-reversible, and can result from increases in endogenous ceramide levels -In addition to ABCA1-mediated cholesterol efflux to lipid free apoA-I, cholesterol is also known to leave the cell via the relatively non-specific aqueous diffusion mechanism (58) in the presence of phospholipid-containing acceptors(59;60).
To determine if ceramide affects this pathway, we studied the effect of ceramide on the efflux of cholesterol from CHO cells to small unilamellar vesicles (SUV) of phospholipid. Figure 4 shows that ceramide had no effect on this transfer. We also found that ceramide did not affect the ability of methylcyclodextrins to remove cholesterol by the same mechanism (data not shown). This indicates that the effect of ceramide is specific for the ABCA1 mediated pathway and argues against the possibility that the ceramide effects observed in Figs. 1-3 are due to a non-specific perturbation of the plasma membrane.
We next examined the kinetics of ceramide-induced cholesterol efflux to apoA-I.
The time course experiment in Figure 5A shows that cells began to exhibit significantly increased cholesterol efflux at approximately 8-10 h after exposure to ceramide. We then measured how long the effect persists in ceramide-stimulated cells after ceramide is removed from the medium. There was a progressive loss of cholesterol efflux ability over time with efflux levels returning to baseline by 16 -24 h (Fig. 5B) . The continuous presence of ceramide in the media, in contrast, maintained enhanced cholesterol efflux.
These data show that the ceramide effect on cholesterol efflux takes several hours to manifest and is a fully reversible phenomenon.
Although C2-ceramide can be found in cellular membranes (61) functionality and trafficking. In the present study, we demonstrate that levels of ceramide can also be a modulator of the ABCA1-mediated cholesterol efflux pathway.
Our data clearly demonstrates that C2-ceramide can induce cholesterol efflux from a variety of cell types. This is true in transformed rodent cells such as CHO and in primary human cells such as the aSMCs. We have also measured a similar effect in mouse peritoneal macrophages (Du and Witting, unpublished result). Thus, the effect is generally applicable and not due to peculiarities within a particular cell type.
Interestingly, ceramide only induced cholesterol efflux in cells actively expressing ABCA1 and did not affect cholesterol efflux via the diffusional pathway. These observations strongly indicate that the effect is specific for ABCA1-mediated cholesterol efflux. The effects of C2-ceramide in this study were not due to cytotoxicity or apoptosis as shown by three different assays and the ability of C2-dihydroceramide to promote the effect. We also found that the effects of C2-ceramide are fully reversible -further arguing against a toxicity or cell death mechanism. Finally, pharmacological treatments known to increase endogenous levels of ceramide showed an increase in cholesterol efflux to apoA-I. In terms of the mechanism of action, ceramide-induced efflux appeared to be a caused by an increase in cellular ABCA1 content. This increase led to an elevated plasma membrane content of ABCAI and enhanced binding of fluorescently-labelled apoA-I. Overall, these findings suggest a link between the ABCA1/apoA-I cholesterol efflux and sphingolipid pathways.
We were intrigued that ceramide increased cholesterol efflux after a relatively long period of 8-10 hours of treatment. One possibility for this delay is that ceramide (or a metabolite of ceramide) must reach a critical concentration in a particular cellular compartment before it exerts an effect on cholesterol efflux. Although, this study did not examine the effects of ceramide on other proteins involved in cholesterol trafficking or efflux to lipoproteins, it is unlikely that ceramide increases ABCAI expression via a transcriptional mechanism. Two different cell lines, RAW macrophages (untreated with cAMP analogs) and HeLa, do not display any increase in ABCAI expression or cholesterol efflux. Thus, ABCAI must already be expressed to mediate any ceramideinduced effect. This supports a post-translational mechanism for ABCA1 regulation.
Ceramide may affect the ABCA1-mediated pathway in a number of ways. The physical properties of ceramides are such that they affect vesicle/membrane fusion events (44) . Therefore, ceramide could be envisioned to act by altering the trafficking of ABCA1 itself. Using GFP-ABCA1 and time-lapse photography, it was shown that GFP-ABCA1 shuttles between the plasma membrane and endocytic compartment (46) . This was added to each well and the slide-wells were incubated on ice for 2 h. Monolayers were then washed, fixed, and coverslipped for imaging on a confocal microscope.
Images are representative fields from the same experiment. Each image was taken within minutes of each other with identical microscope settings.
